Table 1.
Indirect comparison of overall survival and progression free survival. Results of indirect comparison of overall survival are presented in the left lower half, and results from indirect comparison of progression-free survival are presented in the upper-right half.
| PFS HR (95% CI) # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| F | 2.32 (1.39 to 3.88) * | 1.09 (0.76 to 1.55) | 1.03 (0.66 to 1.60) | 1.17 (0.79 to 1.76) | 1.27 (0.85 to 1.90) | 1.77 (1.04 to 3.00) * | 1.06 (0.63 to 1.76) | 1.54 (0.98 to 2.45) | 1.10 (0.72 to 1.68) |
| 1.68 (1.20 to 2.35) * | F-Based | 0.47 (0.32 to 0.68) * | 0.44 (0.28 to0.70) * | 0.51 (0.33 to 0.77) * | 0.55 (0.36 to 0.83) * | 0.76 (0.44 to 1.31) | 0.46 (0.27 to 0.77) * | 0.67 (0.41 to 1.07) | 0.47 (0.31 to 0.73) * |
| 0.96 (0.77 to 1.20) | 0.57 (0.44 to 0.73) * | GEM | 0.94 (0.72 to 1.23) | 1.08 (0.89 to 1.30) | 1.17 (0.97 to 1.41) | 1.62 (1.09 to 2.40) * | 0.97 (0.67 to 1.40) | 1.42 (1.06 to 1.90) * | 1.01 (0.80 to 1.27) |
| 0.90 (0.69 to 1.17) | 0.53 (0.40 to 0.71) * | 0.94 (0.81 to 1.08) | GEM + ANGI | 1.14 (0.82 to1.59) | 1.24 (0.89 to 1.72) | 1.72 (1.07 to 2.77) * | 1.03 (0.65 to 1.62) | 1.50 (1.01 to 2.24) * | 1.07 (0.75 to 1.53) |
| 1.03 (0.80 to 1.33) | 0.61 (0.46 to0.81) * | 1.08 (0.95 to 1.22) | 1.15 (0.96 to 1.39) | GEM + EGFRI | 1.08 (0.83 to 1.42) | 1.50 (0.97 to 2.33) | 0.90 (0.59 to 1.36) | 1.32 (0.93 to 1.86) | 0.93 (0.69 to 1.26) |
| 1.13 (0.88 to 1.45) | 0.67 (0.51 to 0.88) * | 1.17 (1.04 to 1.32) * | 1.25 (1.04 to 1.51) * | 1.09 (0.92 to 1.29) | GEM + F | 1.39 (0.89 to 2.15) | 0.83 (0.55 to 1.26) | 1.21 (0.85 to 1.72) | 0.86 (0.64 to 1.16) |
| 1.30 (0.88 to 1.92) | 0.77 (0.51 to 1.16) | 1.36 (0.98 to 1.87) | 1.45 (1.02 to 2.06) * | 1.26 (0.89 to 1.77) | 1.16 (0.82 to 1.63) | GEM + IMT | 0.60 (0.35 to 1.03) | 0.87 (0.54 to 1.43) | 0.62 (0.39 to 0.98) * |
| 1.07 (0.81 to 1.42) | 0.64 (0.47 to 0.86) * | 1.12 (0.95 to 1.33) | 1.20 (0.96 to 1.49) | 1.04 (0.84 to 1.28) | 0.95 (0.78 to 1.17) | 0.83 (0.57 to 1.19) | GEM + PLA | 1.46 (0.91 to 2.34) | 1.04 (0.67 to 1.61) |
| 1.35 (1.01 to 1.80) * | 0.80 (0.59 to 1.10) | 1.41 (1.17 to 1.69) * | 1.50 (1.19 to 1.90) * | 1.31 (1.05 to 1.63) * | 1.20 (0.96 to 1.50) | 1.04 (0.72 to 1.50) | 1.26 (0.98 to 1.61) | GEM + Taxanes | 0.71 (0.49 to 1.03) |
| 0.97 (0.74 to 1.27) | 0.58 (0.43 to 0.78) * | 1.01 (0.87 to 1.18) | 1.08 (0.88 to 1.33) | 0.94 (0.77 to 1.15) | 0.86 (0.71 to 1.05) | 0.75 (0.52 to 1.07) | 0.90 (0.72 to 1.14) | 0.72 (0.57 to 0.92) * | GEM + TKI |
| OS HR (95% CI) # | |||||||||
# Comparisons between treatments were read from left to right, and the estimate (hazard ratio, HR) with 95% confidence interval for a given comparison was read in the intersection of two treatments. In the left lower half and upper-right half, estimates with p < 0.05 favored the column-defining treatment. * Denotes p-value < 0.05. PLA: doublet platinum-based treatment; GEM: gemcitabine; F: fluoropyrimidine only; F-based: fluoropyrimidine-based treatment; EGFRI: epidermal growth factor receptor inhibitor; ANGI: angiogenesis inhibitor; IMT: immunotherapy; TKI: tyrosine kinase inhibition.